Liraglutide explained: daily dosing, evidence, and key distinctions

Liraglutide is a GLP-1 receptor agonist given as a once-daily injection under the skin. In the U.S. it is sold under two brand names with different labeled uses: Victoza (type 2 diabetes) and Saxenda (chronic weight management). Ask your pharmacist which exact product is available. It is an older, daily medicine, and other GLP-1 products are given weekly. This page does not recommend one over another.

Quick answer

Liraglutide is a GLP-1 receptor agonist given as a once-daily injection under the skin. In the U.S. it is sold under two brand names with different labeled uses: Victoza (type 2 diabetes) and Saxenda (chronic weight management). Ask your pharmacist which exact product is available. It is an older, daily medicine, and other GLP-1 products are given weekly. This page does not recommend one over another.

Labeled products and uses

  • Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Source: Victoza label, DailyMed.
  • Saxenda is indicated, with a reduced-calorie diet and more physical activity, for chronic weight management in adults with BMI 30 or higher, or 27 or higher with at least one weight-related condition, and in patients 12 and older with body weight above 60 kg and obesity. Source: Saxenda label.
  • Both contain liraglutide, and the Victoza label says coadministration with other liraglutide-containing products is not recommended.
  • Availability depends on the exact product, manufacturer and pharmacy. Ask your pharmacist which product is being dispensed.

How it is used

Both products are given as a once-daily injection under the skin, using a pen. Treatment starts at a low dose that is increased over several weeks, and the schedule differs by product and person. Your prescriber sets the plan, and your product’s Medication Guide and Instructions for Use explain how to use the pen. This page gives no administration steps or dosing schedule.

Evidence snapshot

Liraglutide landmark trials

Liraglutide landmark trials

  • SCALE (weight). 3,731 adults with BMI of 30 or more, or 27 or more with high cholesterol or blood pressure, no type 2 diabetes. After 56 weeks on liraglutide 3.0 mg plus lifestyle counseling, mean weight change was -8.4 kg versus -2.8 kg on placebo (difference -5.6 kg). 33.1% on liraglutide versus 10.6% on placebo lost more than 10% of body weight. Sources: Pi-Sunyer et al., NEJM 2015.
  • LEADER (heart events). 9,340 adults with type 2 diabetes and high cardiovascular risk, median follow-up 3.8 years. The primary outcome (cardiovascular death, nonfatal heart attack or nonfatal stroke) occurred in 13.0% on liraglutide and 14.9% on placebo (hazard ratio 0.87). Source: Marso et al., NEJM 2016.
  • Real-world example. In a retrospective study of 277 patients at one Swiss obesity clinic, median time on liraglutide 3.0 mg was 6.8 months, 13.7% reached the 3.0 mg dose, and mean weight change at 7 months was -4.1 kg (-4.2%). This is one clinic, not a controlled trial. Source: Karger, 2021.

Safety and comparison

The Saxenda label has a boxed warning: liraglutide caused thyroid C-cell tumors in rodents, it is not known whether it does in humans, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Its other warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia when used with insulin secretagogues, heart rate increase (monitor at regular intervals), acute kidney injury from volume depletion (monitor renal function if volume-depleting reactions occur), severe gastrointestinal reactions and hypersensitivity. Source: Saxenda label. In LEADER, the most common adverse events leading to stopping were gastrointestinal.

On comparison: liraglutide is a daily injection, while Wegovy and Zepbound are weekly. Their trials had different populations, designs and lengths, so these results do not tell you which works better for you. See the half-life article for how each product’s half-life differs. Switching is a prescriber decision.

What this does not establish

SCALE excluded people with type 2 diabetes, and LEADER enrolled only people with diabetes, so the two results should not be read together. Averages do not predict an individual result. The Swiss data come from one clinic. Dosing changes, switching and stopping are prescriber decisions.

FAQs

What is liraglutide? A once-daily GLP-1 receptor agonist injection sold as Victoza (type 2 diabetes) and Saxenda (weight management), with generics.

What does human research show about liraglutide? In SCALE, average weight loss was 8.4 kg versus 2.8 kg on placebo over 56 weeks. In LEADER, fewer major cardiovascular events occurred than with placebo in adults with type 2 diabetes.

What safety questions remain about liraglutide? Thyroid C-cell tumor risk in humans is unknown, and long-term and real-world outcomes vary. Generic availability and labeled uses can change, so check current labels.

Sources

  1. Victoza label, DailyMed
  2. Saxenda label (indications), DailyMed
  3. Saxenda label (warnings)
  4. Pi-Sunyer et al., SCALE, N Engl J Med 2015
  5. Marso et al., LEADER, N Engl J Med 2016
  6. Real-world liraglutide 3.0 mg, Swiss obesity clinic, Karger 2021

Source methods and reading limits

Sources checked against Europe PMC abstracts and product-label text: November 17, 2026. Full text was not read for abstract-only claims. Source dates and reading limits are recorded with the supporting references.